Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis

Background. Immune checkpoint inhibitors (ICIs) have been evaluated as neoadjuvant treatment in urothelial carcinoma (UC) patients, with these agents reporting encouraging pathologic complete response (pCR) rates. Herein, we performed a systematic review and meta-analysis aimed at evaluating the inc...

Full description

Bibliographic Details
Main Authors: Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Gennaro Palmiotti, Francesco Massari
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Journal of Clinical Medicine
Subjects:
immunotherapy
immune checkpoint inhibitors
pembrolizumab
atezolizumab
urothelial carcinoma
neoadjuvant
Online Access:https://www.mdpi.com/2077-0383/11/4/1038

Internet

https://www.mdpi.com/2077-0383/11/4/1038

Similar Items